arrow
A

Anders Lindholm Sørensen

University of Southern Denmark
H指数:15
被引数:740

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Interferon-α vs hydroxyurea in patients with myeloproliferative neoplasms (DALIAH): a multicentre, randomised, open-label, phase 3 trial in Denmark

干扰素-α与羟基脲在骨髓增殖性肿瘤患者中的比较(DALIAH):一项在丹麦进行的为期3期的多中心、随机、开放标签临床试验

2026-09-010
OAAI
TGF-β-specific T cells are frequent in peripheral blood and bone-marrow from patients with myeloproliferative neoplasms

TGF-β特异性T细胞在骨髓增生性肿瘤患者的外周血和骨髓中较为常见。

Leukemia
IF13.4
2025-11-100
PRE
The JAK2V617F and CALR mutations and risk of cancer, cardiovascular diseases, and all-cause mortality

JAK2V617F和CALR突变与癌症、心血管疾病及全因死亡率的风险

2025-11-060
OAAI
Statins Enhance the Efficacy of Pegylated Interferon-α2 in Philadelphia-Negative Chronic Myeloproliferative Neoplasms

他汀类药物增强聚乙二醇干扰素-α2在费城染色体阴性慢性骨髓增殖性肿瘤中的疗效

2025-09-220
OAAI
Statins Enhance the Efficacy of Pegylated Interferon-alpha2 in Patients with Ph-Negative Chronic Myeloproliferative Neoplasms. Results from a Danish Single-Institution Cohort Study

他汀类药物增强聚乙二醇干扰素-α2在Ph阴性慢性骨髓增殖性肿瘤患者中的疗效。丹麦单机构队列研究的结果。

BLOOD
IF23.1
2024-11-051
PRE
Neutrophil-to-lymphocyte ratio and all-cause mortality with and without myeloproliferative neoplasms-a Danish longitudinal study
2024-02-099
OAAI
Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study
2020-06-0570
OAAI
JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation
LEUKEMIA
IF13.4
2018-11-2343
PREAI